StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.86−0.17 (-2.12%)

Close on Nov 13, 2026Market cap $1.59BP/E –Yield –

SELLAS Life Sciences total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

SELLAS Life Sciences's total debt was $0 at Dec 31, 2018. For fiscal 2018 it was $0, down 100.0% from the year before. The highest annual figure on record is $16.40M in fiscal 2016.

Annual total debt

PeriodPeriod endValueChange
FY2018Dec 31, 2018$0-100.0%
FY2017Dec 31, 2017$10.99M-33.0%
FY2016Dec 31, 2016$16.40M+246.0%
FY2015Dec 31, 2015$4.74M-43.6%
FY2014Dec 31, 2014$8.40M-15.1%
FY2013Dec 31, 2013$9.89M–
FY2012Dec 31, 2012$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2018Dec 31, 2018$0-100.0%
Q3 FY2018Sep 30, 2018$76.00K-99.4%
Q2 FY2018Jun 30, 2018$7.78M-40.3%
Q1 FY2018Mar 31, 2018$9.68M-23.2%
Q4 FY2017Dec 31, 2017$10.99M-33.0%
Q3 FY2017Sep 30, 2017$12.17M–
Q2 FY2017Jun 30, 2017$13.03M–
Q1 FY2017Mar 31, 2017$12.60M–
Q4 FY2016Dec 31, 2016$16.40M–

More SELLAS Life Sciences figures

See a number that looks wrong?